GlassScriptPhysician profile
Ashvini Sengar
NPI 1376520254
$11,164.95
in general payments reported to CMS, 2019-2025
68 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,776 · 2020: $918 · 2021: $2,213 · 2022: $1,744 · 2023: $893 · 2024: $2,311 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,246 · Long Term Medical Supply Or Device Loan: $167 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,245.70 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $100.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,463.07 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $877.61 | 2019-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $686.79 | 2019-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $506.56 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $489.16 | 2019-2025 | Keytruda, Lynparza |
| Eisai INC. | $356.76 | 2019-2024 | |
| Abbvie INC. | $346.64 | 2019-2025 | |
| Pfizer INC. | $322.72 | 2019-2025 | |
| Celgene Corporation | $321.23 | 2019-2025 | Reblozyl, Pomalyst |
| Amgen INC. | $307.64 | 2019-2023 | Lumakras |
| Asd Specialty Healthcare, LLC | $263.53 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $232.93 | 2019-2025 | Imfinzi, Enhertu |
| Array Biopharma INC | $172.23 | 2023-2025 | Braftovi, Mektovi, Tukysa |
| Elekta, INC. | $161.29 | 2019-2021 | |
| Gilead Sciences, INC. | $161.18 | 2019-2025 | Trodelvy |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashvini Sengar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.